abcdefghijklmn
opqrstuvwxyz
Test Menu
Test Change Details
Allergy & Immunology
Cardiology & Coagulation
Dermatopathology
Endocrinology
Gastroenterology
Genetics
Hepatology
Infectious Disease
Microbiology
Nephrology
Neurology
Oncology
Pathology
Pediatrics
Rheumatology
Toxicology
Urology
Women's Health
92063: Cardio IQ® Diabetes and ASCVD Risk Panel with Scores Print View
Glucose     mg/dL 
Hemoglobin A1c      
Cholesterol, Total   < 20 years: 125 - 170
>= 20 years: 125 - 200 
mg/dL 
HDL Cholesterol   view ref range  mg/dL 
Triglycerides   view ref range  mg/dL 
LDL Chol, Calculated   < 2 years: Call Client Services
< 21 years: < 110
>= 21 years: < 130 
mg/dL 
Cholesterol/HDL Ratio   < 5.1  calc 
Non-HDL Cholesterol   < 20 years: < 120
>= 20 years: Call Client Services 
mg/dL 
10 Year ASCVD Risk     % 
10 Year ASCVD Risk Goal     % 
Lifetime ASCVD Risk     % 
8 Year Diabetes Risk     % 
Height Feet     ft 
Height Inches     in 
Weight     lbs 
Calculated BMI      
African American      
Systolic Blood Pressure     mmHg 
Diastolic Blood Pressure     mmHg 
Treatment for High B.P.      
Diabetes      
Parental History of Diab      
Current Smoker      

PRIMARY
1 Serum 4 (2) mL   Frozen - 15 Day(s)/Refrigerated - 7 Day(s)/Room Temperature - 48 Hour(s)  
2 Whole Blood EDTA 1 (0.5) mL   Frozen - 6 Month(s)/Refrigerated - 7 Day(s)/Room Temperature - 7 Day(s)  
ALTERNATE

The increasing prevalence of obesity has led to an epidemic of diabetes mellitus and related complications, including ASCVD. Prediction of the risk of ASCVD and of developing diabetes in the Cardio IQ(R) lab report will simplify and improve the communication of those risks to patients. This panel provides the 10-year and life time risk of ASCVD events and the 8-year risk of developing diabetes. The lipid panel results will aid in the assessment of ASCVD. Assessment of 10-year risk of a risk of a first atherosclerotic cardiovascular (ASCVD) event is recommended by the 2013 ACC/AHA Guidelines on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults. These guidelines recommend initiating statin therapy based on 10-year ASCVD risk score. Assessment of 8-year risk of developing diabetes mellitus is based on laboratory test results with anthropomophic data and family history. This algorithm was developed in the Framingham cohort, and is intended to aid in the identification of patients at risk for developing diabetes, permitting Pharmacology or lifestyle interventions.

The assay manufacturer, Roche, notes that N-acetylcysteine, when
administered in high concentrations (such as for treatment of
acetaminophen overdose), can interfere with their assay for HDL
cholesterol, leading to falsely low results.

For risk calculations to be performed, the following patient-specific
information must be provided at the time of order:
Age: Years
Gender: M (for male) or F (for female)
Height Feet: Feet
Height Inches: Inches
Weight: lbs
Race - African American: Y (for yes) or N (for no)
Systolic Blood Pressure: mmHg
Diastolic Blood Pressure: mmHg
Treatment for High Blood Pressure: Y (for yes) or N (for no)
Diabetes Status: Y (for yes) or N (for no)
Parental History of Diab: Y (for yes) or N (for no)
Smoking Status: Y (for yes) or N (for no)
Patient should fast 9-12 hours prior to collection.
The assay manufacturer Beckman Coulter advises: "N-Acetyl Cysteine
(NAC), when administered in therapeutic concentrations (for the
treatment of acetaminophen overdose), has been...determined to
interfere with assays for...Cholesterol, Uric Acid" where "NAC
interference may lead to falsely low results." According to Beckman
Coulter, the NAC interference should be insignificant by 12 hours
after completion of the initial loading dose of an IV infusion
treatment regimen consisting of an initial loading dose of 150 mg/kg
administered over 1 hr, a second dose of 50 mg/kg administered over
4 hrs and a third dose of 100 mg/kg administered over 16 hrs.
Setup Schedule
Monday-Friday

Reported (Analytical Time)
3 days

CPT Codes
82947,83036,82465,83718,84478

The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Notes
Reject Criteria: Red-top (no-gel); gross hemolysis; moderately to grossly icteric; sodium fluoride/oxalate (grey-top) tube; heparinized plasma Transport Temperature: Refrigerated Methodology: Spectrophotometry, Immunoturbidimetry, Enzymatic Additional Information If Triglyceride is >400 mg/dL, then the Cardio IQ(R) Direct LDL will be performed at an additional charge (CPT code 83721).






© 1996 - 2017 Quest Diagnostics Nichols Institute of Valencia
For test information, please call Client Services at 800-421-4449.

San Francisco Web Design & Database